1
项与 Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion) 相关的临床试验Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.
Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.
100 项与 Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion) 相关的临床结果
100 项与 Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion) 相关的转化医学
100 项与 Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion) 相关的专利(医药)
100 项与 Autologous CAR19 T lymphocytes(Institute of Hematology and Blood Transfusion) 相关的药物交易